AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

Vertex Pharmaceuticals is in a new era, but should continue to be a big winner for investors. stocks we like better than ...

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has also been expanding its offerings into solid tumors. Its ...

CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation antigenxCD3 bispecific T-cell engager (BiTE), and Amgen’s Kyprolis ...

Antibody-Drug Conjugates (ADC) Market- Driven by Advanced Payload Technologies and Strategic Industry Partnerships Sai Kumar DataM Intelligence 4market Research LLP +1 877-441-4866 ... Visit us on ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...